Entity

Time filter

Source Type


Qin X.F.,Zhengzhou University | Zhao L.S.,Zhengzhou University | Chen W.R.,PLA General Hospital at Beijing | Yin D.W.,PLA General Hospital at Beijing | Wang H.,PLA General Hospital at Beijing
Clinical Nutrition | Year: 2015

Background & aims: Lipid abnormalities are regarded as a risk factor for cardiovascular disease. Low vitamin D status has been shown to be associated with hyperlipidemia. We planned to research the effects of vitamin D supplementation as an adjuvant therapy for patients with hypercholesterolemia. Methods: Patients with hypercholesterolemia were enrolled in this single-center, double-blind, placebo-controlled trial in Beijing (39°54'N). Fifty-six patients were randomly assigned to receive vitamin D (n=28, 2000IU/d) or a placebo (n=28) as an add-on to statin, by the method of permutated block randomization. Serum lipid levels were evaluated at baseline, 1, 3 and 6 months. Results: Vitamin D supplementation resulted in increased serum 25-hydroxyvitamin D concentrations compared with placebo (+16.3±11.4 compared with+2.4±7.1ng/ml; p<0.001). At 6 months, the primary end point, a difference in the fall of serum total cholesterol levels between the vitamin D and placebo groups after 6 months of treatment was significant-22.1mg/dl (95% CI-32.3;-12.2) (p<0.001). The difference between the groups in the fall of serum triglyceride levels after 6 months of treatment was-28.2mg/dl (95% CI-48.8;-8.4) (p<0.001). In patients with 25-hydroxyvitamin D level<30ng/ml at baseline (n=43), the serum total cholesterol and triglyceride levels were reduced by-28.5±11.9mg/dl (p<0.001) and-37.1±19.5mg/dl (p<0.001), respectively. Conclusions: Vitamin D supplementation might improve serum lipid levels in statin-treated patients with hypercholesterolemia, it might be an adjuvant therapy for patients with hypercholesterolemia. Clinical Trials Registration Number - NCT02009787. © 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. Source


Chen W.-R.,PLA General Hospital at Beijing | Shen X.-Q.,International Medical Center | Zhang Y.,PLA General Hospital at Beijing | Chen Y.-D.,PLA General Hospital at Beijing | And 6 more authors.
Endocrine | Year: 2015

The influence of glucagon-like peptide-1 has been studied in several studies in patients with acute myocardial infarction, but not in patients with non-ST-segment elevation myocardial infarction (NSTEMI). We planned to evaluate the effects of liraglutide on left ventricular function in patients with NSTEMI. A total of 90 patients were randomized 1:1 to receive either liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days) or placebo for 7 days. Eighty-three patients completed the trial. Transthoracic echocardiography was used to assess left ventricular function. At 3 months, the primary endpoint, the difference in the change in left ventricular ejection fraction between the two groups was +4.7 % (liraglutide vs. placebo 95 % CI +0.7 to +9.2 % P = 0.009) under intention-to-treat analysis. The difference in decrease in serum glycosylated hemoglobin levels was −0.2 % (liraglutide vs. placebo 95 % CI −0.1 to −0.3 %; P < 0.001). Inflammation and oxidative stress improved significantly in the liraglutide group compared to the placebo group. Liraglutide could improve left ventricular function in patients with NSTEMI, making it a potential adjuvant therapy for NSTEMI. © 2015 Springer Science+Business Media New York Source


Chen W.R.,PLA General Hospital at Beijing | Qian Y.A.,Lujiang Peoples Hospital | Chen Y.D.,PLA General Hospital at Beijing | Shi Y.,PLA General Hospital at Beijing | And 5 more authors.
Heart Lung and Circulation | Year: 2014

Purpose: Coronary Artery Disease (CAD) remains a major cause of morbidity and mortality in the world. Low vitamin D status has been shown to be associated with increased risk of developing cardiovascular disease, hypertension and obesity. We planned to research the association between low vitamin D status and the severity of CAD. Procedures: A total of 348 consecutive patients undergoing coronary angiography for evaluation of CAD were included in this study. 25-Hydroxyvitamin D [25(OH)D] was measured by chemiluminescence assay. CAD severity was assessed by using the SYNTAX scores. The data presented are the mean levels/values and standard deviation. Findings: The serum 25(OH)D level of CAD patients was 18.2. ±. 10.6. ng/ml. The SYNTAX scores were 27.8. ±. 8.5. In a multivariate linear regression analysis (adjusted for age, high-sensitivity C-reactive protein, SYNTAX score, parathyroid hormone, body mass index, haemoglobin and creatinine), the serum 25(OH)D level showed a negative correlation with SYNTAX score and high-sensitivity C-reactive protein (hsCRP) level. Logistic regression analysis identified 25(OH)D as an independent factor related to high SYNTAX scores. Patients whose vitamin D levels were in the lowest 25(OH)D category (<20. ng/ml) were more often in the high SYNTAX scores group, with their incidence about two-fold higher than those in the highest 25(OH)D category (>30. ng/ml). Conclusion: Low vitamin D is associated with the severity of coronary artery stenosis. © 2013. Source


Chen W.R.,PLA General Hospital at Beijing | Chen Y.D.,PLA General Hospital at Beijing | Shi Y.,PLA General Hospital at Beijing | Yin D.W.,PLA General Hospital at Beijing | And 2 more authors.
Journal of Cardiovascular Medicine | Year: 2015

Aims Low vitamin D status has been shown to be associated with coronary artery disease; most studies have involved in adults, but few have involved elderly people. We planned to research the association between vitamin D, parathyroid hormone (PTH) and coronary artery disease in elderly people.Methods A population-based study was conducted among 1245 Chinese participants, aged 60-102 years, in the spring of 2013. Serum 25-hydroxyvitamin D (25 (OH)D) was measured by chemiluminescence assay. The levels of PTH were measured by the electrochemiluminescence immunoassay (ECLIA) method.Results One thousand two hundred and forty-five participants, including 543 women (43.6%), were evaluated in 2013. The median concentrations of serum 25 (OH)D and PTH for the entire group were 16.8 ng/ml and 41.0 pg/ml, respectively. The prevalence rates of diabetes, hypertension, hyperlipidemia and coronary artery disease were significantly different across the 25 (OH)D quartiles. The prevalence rates of diabetes, hypertension, hyperlipidemia and coronary artery disease were also significantly different across the PTH quartiles. In logistic regression analyses, serum25 (OH)D levels were associated with risk of coronary artery disease in single and multiple regression models (P<0.05). Serum PTH levels were also associated with the risk of coronary artery disease in single and multiple regression models (P<0.05). Subgroup analyses stratified by sex or age yielded similar results.Conclusions Serum vitamin D and PTH levels are independently associated with risk of coronary artery disease in a Chinese elderly population. © 2015 Italian Federation of Cardiology. Source


Chen W.R.,PLA General Hospital at Beijing | Liu Z.Y.,PLA General Hospital at Beijing | Shi Y.,PLA General Hospital at Beijing | Yin D.W.,PLA General Hospital at Beijing | And 3 more authors.
Atherosclerosis | Year: 2014

Objectives: Low vitamin D status has been shown to be associated with hypertension. We planned to research the effect of vitamin D and nifedipine in the treatment of patients with essential hypertension. Methods: Patients with grades I-II essential hypertension were enrolled in this single-center, double-blind, placebo-controlled trial in Beijing. All patients received a conventional antihypertensive drug (nifedipine, 30. mg/d). One hundred and twenty-six patients were randomly assigned to receive vitamin D (n= 63, 2000. IU/d) or a placebo (n= 63) as an add-on to nifedipine, by the method of permutated block randomization. Ambulatory blood pressure monitoring was performed at baseline (month 0), at month 3 and at month 6. Results: In vitamin D supplementation group, there was a significant increase in mean 25-hydroxyvitamin D levels from baseline (19.4 ± 11.6. ng/ml) to 6 months (34.1 ± 12.2. ng/ml; p< 0.001). At 6 months, the primary end points, a difference in the fall of 24-h mean blood pressure, between the groups was-6.2. mm. Hg (95% CI-11.2;-1.1) for systolic blood pressure (p<. 0.001) and-4.2. mm. Hg (95% CI-8.8;-0.3) for diastolic blood pressure (p< 0.001) under intention to treat analysis. In patients with vitamin D <30. ng/ml at baseline (n= 113), 24-h mean blood pressure decreased by 7.1/5.7. mm. Hg (p<. 0.001). Safety and tolerability were similar among the two groups. Conclusions: Vitamin D supplementation can reduce blood pressure in patients with hypertension, it can be an adjuvant therapy for patients with grades I-II essential hypertension. Clinical Trial Registration: This study was registered in the Chinese Clinical Trial Registry, it is available in Website: http://www.chictr.org/cn/; Registration number: ChiCTR-ONC-13003840. © 2014 Elsevier Ireland Ltd. Source

Discover hidden collaborations